跳至主要内容
临床试验/NCT01210170
NCT01210170已完成不适用

Acute Effect of Mometasone Furoate DPI on Beta-adrenergic Airway and Airway Vascular Relaxation in Moderately Severe Asthma

University of Miami1 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2010年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
22
试验地点
1
主要终点
Albuterol-induced Change in FEV1

研究概览

简要总结

Glucocorticosteroids inhibit the disposal of organic cations by blocking organic cation transporters expressed by non-neuronal cells, thereby interfering with the inactivation of the organic cations by intracellular enzymes. Beta2-adrenergic agonists are organic cations, and the concentration of inhaled beta2-adrenergic agonists at beta2-adrenergic receptor sites on smooth muscle is likely to be increased by inhaled glucocorticosteroids (ICS) by the ICS' effect on the glucocorticosteroid-sensitive organic cation transporters. The investigators have shown in human airway vascular smooth muscle cells that the glucocorticosteroid action on organic cation uptake occurs within minutes, does not involve gene transcription or protein synthesis, is not mediated through classical steroid receptors, and is cell membrane-linked.

In the present proposal, the investigators wish to use different single doses of mometasone, a clinically effective ICS, administered with or at different times before albuterol inhalation in subjects with moderate persistent asthma who are obstructed at the time of study.

With this approach the investigators will test the hypothesis that a single inhalation of mometasone causes an acute, transient, dose-dependent potentiation of beta2-adrenergic bronchodilation.

If the hypothesis that a single dose of mometasone acutely potentiates beta2-adrenergic bronchodilation is correct, the results would have a significant impact on treatment strategies involving ICSs and beta2-adrenergic agonists in patients with asthma.

详细描述

Fifteen non-smokers (males and females between the ages of 18 and 65 years) with physician-diagnosed moderate persistent asthma will be recruited for the study. The subjects will be allowed to use inhaled controller (including ICS) and rescue medication. At study entry, all asthmatic subjects must be clinically stable, and have a forced pre-bronchodilator one-second expired volume (FEV1) of < 75% predicted.

Approval for the protocol will be requested from the University of Miami Institutional Review Board. All subjects will provide written informed consent.

Exclusion criteria:

  • Cardiovascular disease and use of cardiovascular medications
  • Pregnancy
  • Use of oral controller medication for asthma (methylxanthines, systemic glucocorticosteroids, leukotriene modifiers)
  • An acute respiratory infection within 4 weeks before enrollment.

Each subject will make 8 visits to the research laboratory.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Other
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Fifteen non-smokers (males and females between the ages of 18 and 65 years) with physician-diagnosed moderate persistent asthma and FEV1 < 75% of predicted.

排除标准

  • Cardiovascular disease and use of cardiovascular medications, pregnancy, use of oral controller medication for asthma (methylxanthines, systemic glucocorticosteroids, leukotriene modifiers), an acute respiratory infection within 4 weeks before enrollment

研究组 & 干预措施

mometasone 400 mcg - 30 min

Experimental

randomly assigned intervention

干预措施: mometasone 400 mcg (Drug)

mometasone 400 mcg simultaneous

Experimental

randomly assigned intervention

干预措施: mometasone 400 mcg (Drug)

placebo- 30 min

Placebo Comparator

randomly assigned intervention

干预措施: placebo (Drug)

placebo simultaneous

Placebo Comparator

randomly assigned intervention

干预措施: placebo (Drug)

mometasone 400 mcg - 60 min

Experimental

randomly assigned intervention

干预措施: mometasone 400 mcg (Drug)

placebo- 60 min

Placebo Comparator

randomly assigned intervention

干预措施: placebo (Drug)

mometasone 200 mcg - 30 min

Experimental

randomly assigned intervention

干预措施: mometasone 200 mcg (Drug)

mometasone 200 mcg - 60 min

Experimental

randomly assigned intervention

干预措施: mometasone 200 mcg (Drug)

mometasone 200 mcg simultaneous

Experimental

randomly assigned intervention

干预措施: mometasone 200 mcg (Drug)

结局指标

主要结局

Albuterol-induced Change in FEV1

时间窗: 15 minutes after albuterol inhalation

FEV1 will be measured before and after inhalation of 180 mcg albuterol.

次要结局

  • Albuterol Induced Percent Change in Qaw(change in Qaw 15 minutes after albuterol inhalation)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Adam Wanner

Professor of Medicine

University of Miami

研究点 (1)

Loading locations...

相似试验